AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 04/06/24

2024-04-06 09:26:54 ET More on Amneal, Bausch Health, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health: A Timely Divestiture Is The Key To An Higher Val...

- Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Execut...

2024-03-25 17:15:09 ET Gainers: Stoke Therapeutics ( STOK ) +87% . AnaptysBio ( ANAB ) +8% . Amneal Pharmaceuticals ( AMRX ) +6% . Omega Therapeutics ( OMGA ) +5% . MoneyHero  ( MNY ) +5% . Losers: Ocular Therapeutix...

- Product references branded Ciprodex - Represents another complex, high value new product Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) ...

2024-03-01 07:27:26 ET DENVER, Colo., Mar 01, 2024 ( 247marketnews.com )- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX ) reported its fourth quarter and full year 2023 financial results, this morning. Its full year 2023 net revenue was $2.39 billion and projects 2024 financial gui...

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom...

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference. Barclays 26th Annual Global Healthcare Conference March 13, 2024 Miami, FL Fireside chat – 8:30 AM ET One-on-one...

2024-02-12 09:36:15 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers F...

2024-02-08 17:12:51 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Amneal Pharma inks licensing pact with Knight Therapeutics Amneal announces move to Nasdaq Seeking Alpha’s Quant Rating ...

BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral f...